{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:17:53Z","timestamp":1791076673166,"version":"4.1.0"},"reference-count":142,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1517\/17425240802652309","type":"journal-article","created":{"date-parts":[[2009,1,10]],"date-time":"2009-01-10T01:16:25Z","timestamp":1231550185000},"page":"71-89","source":"Crossref","is-referenced-by-count":82,"title":["Recent advances in liposomal dry powder formulations: preparation and evaluation"],"prefix":"10.1517","volume":"6","author":[{"given":"Ambikanandan","family":"Misra","sequence":"first","affiliation":[{"name":"Faculty of Technology and Engineering The Maharaja Sayajirao University of Baroda, Pharmacy Department, Kalabhavan, Vadodara 390 001, Gujarat State, India ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaustubh","family":"Jinturkar","sequence":"additional","affiliation":[{"name":"Faculty of Technology and Engineering The Maharaja Sayajirao University of Baroda, Pharmacy Department, Kalabhavan, Vadodara 390 001, Gujarat State, India ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Patel","sequence":"additional","affiliation":[{"name":"Faculty of Technology and Engineering The Maharaja Sayajirao University of Baroda, Pharmacy Department, Kalabhavan, Vadodara 390 001, Gujarat State, India ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigar","family":"Lalani","sequence":"additional","affiliation":[{"name":"Faculty of Technology and Engineering The Maharaja Sayajirao University of Baroda, Pharmacy Department, Kalabhavan, Vadodara 390 001, Gujarat State, India ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahavir","family":"Chougule","sequence":"additional","affiliation":[{"name":"Florida A&amp;M University, College of Pharmacy, Tallahassee, FL 32307, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,1,9]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i2-3.20"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.03.014"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1976.tb04879.x"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600750502"},{"key":"e_1_3_1_6_1","unstructured":"Metered Dose Inhalers: Devices Drugs and Delivery Strategies Sept 2006; Available from: http:\/\/www.greystoneassociates.org\/MDIPercent20Prospectus.pdf [Last accessed 15 August 2008]"},{"key":"e_1_3_1_7_1","first-page":"367","volume":"50","author":"Joseph","year":"2005","unstructured":"Joseph RL. The inhalation of drugs: Advantages and problems. Respir care 2005;50(3):367-82","journal-title":"Respir care"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(95)04233-4"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.45.6.469"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62146-1"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448060-00006"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720108783954815"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/copd.2006.1.3.251"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(00)00275-3"},{"key":"e_1_3_1_15_1","first-page":"58","volume":"08","author":"Hickey","year":"1994","unstructured":"Hickey AJ, Concessio NM, Platz RM, et al. Factors influencing the dispersion of dry powders as aerosols. Pharm Technol 1994;08:58-84","journal-title":"Pharm Technol"},{"key":"e_1_3_1_16_1","first-page":"1313","volume":"50","author":"Geller","year":"2005","unstructured":"Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50(10):1313-22","journal-title":"Respir Care"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2001.1276"},{"key":"e_1_3_1_18_1","first-page":"314","volume":"41","author":"Shek","year":"1986","unstructured":"Shek PN, Barber RF. Liposomes: a new generation of drug and vaccine carriers. Mod Med 1986;41:314-26","journal-title":"Mod Med"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408447809029333"},{"key":"e_1_3_1_20_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0031-6997(25)06651-7","volume":"36","author":"Poznansky","year":"1984","unstructured":"Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: A critical review. Pharmacol Rev 1984;36:277-336","journal-title":"Pharmacol Rev"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.47.4.257"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.1.23"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i45.40"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(99)00122-2"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.1.1.67"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/jam.2006.19.21"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(00)00275-3"},{"key":"e_1_3_1_28_1","unstructured":"Bystrom K Nilsson PG. Powders for inhalation. US6045828; 1996"},{"key":"e_1_3_1_29_1","unstructured":"Parmar M. Formulation of insoluble small molecule therapeutics in lipid-based carriers. US20060051406A1; 2006"},{"key":"e_1_3_1_30_1","unstructured":"Weers JG Tarara T Tzannis S. Lipid formulations for spontaneous drug encapsulation. US20050214224A1; 2005"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/10837450600939099"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007544804864"},{"key":"e_1_3_1_33_1","first-page":"3898","author":"Katsuto","year":"2001","unstructured":"Katsuto O, Tomohiro, Masahiko A, et al. Development of a New Preparation Method of Liposomes Using Supercritical Carbon Dioxide. Langmuir 2001;(17):3898-390","journal-title":"Langmuir"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0032-5910(75)80021-0"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.38.12.881"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/jam.1994.7.49"},{"key":"e_1_3_1_37_1","unstructured":"Hickey AJ. Summary of common approaches to pharmaceutical aerosol administration; Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker New York; 1992:255-88"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7062.895"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(97)00508-5"},{"key":"e_1_3_1_40_1","first-page":"101","volume":"3","author":"Ganderton","year":"1992","unstructured":"Ganderton D. The generation of respirable cloud from coarse powder aggregates. J Biopharm Sci 1992;3:101-5","journal-title":"J Biopharm Sci"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8502(96)00021-3"},{"key":"e_1_3_1_42_1","unstructured":"Steckel H Muller BW. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in passivation effects. In: Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society London UK 1996:86-9"},{"key":"e_1_3_1_43_1","unstructured":"Zeng XM Tee SK Marriott C et al. Effect of mixing procedure and particle size distribution of carrier particles on the deposition of salbutamol sulphate from dry powder inhaler formulations. In Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society London UK; 1996:40-3"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717540490467375"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221107779814159"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1208\/pt050465"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1208\/pt060480"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1208\/pt060360"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1208\/pt020425"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.2003.03813.x"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1208\/pt050113"},{"key":"e_1_3_1_52_1","unstructured":"Woolfe AJ Zheng XM Langford A. Methods to produce powders for pulmonary or nasal administration. WO0113885; 2001"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2004.07.022"},{"key":"e_1_3_1_54_1","unstructured":"Kussendrager KD Ellison MJH. Carrier material for dry powder inhalaltion. WO20020207705; 2002"},{"key":"e_1_3_1_55_1","first-page":"L374","volume":"268","author":"Briscoe","year":"1995","unstructured":"Briscoe P, Caniggia I, Graves A, et al. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am J Physiol 1995;268:L374-80","journal-title":"Am J Physiol"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.09.010"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S2.4.675"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-007-9024-6"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2006.405"},{"key":"e_1_3_1_60_1","first-page":"33","volume":"2","author":"Sunkara","year":"1999","unstructured":"Sunkara G, Kompella U. Drug Delivery Applications of Supercritical Fluid Technology. Drug Deliv Technol 1999;2:33-34","journal-title":"Drug Deliv Technol"},{"key":"e_1_3_1_61_1","first-page":"173","volume":"18","author":"Kompella","year":"2001","unstructured":"Kompella U, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carrier Syst 2001;18(2):173-99","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2007.08.003"},{"key":"e_1_3_1_63_1","unstructured":"Misra A Parmar N Naik S et al. Preparation of Amphotericin B liposomes by supercritical fluid technology IN391\/MUM\/2008; 2008"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.suppl_2.S61"},{"key":"e_1_3_1_65_1","doi-asserted-by":"crossref","unstructured":"Akwete LA Hsu L. Leuprolide and other LH-RH analogues in stability and characterization of protein and peptide drugs: case histories. In: Wang YJ Pearlman R eds. Formation Characterization and Stability of Protein Drugs. New York NY: Plenum Press; 1993:159-99","DOI":"10.1007\/978-1-4899-1236-7_5"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.02.003"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010072129578"},{"key":"e_1_3_1_68_1","unstructured":"Goel BK. Medical Laboratory Technology. Vol. III. New Delhi India Tata McGraw-Hill; 1988:1031"},{"key":"e_1_3_1_69_1","unstructured":"Betagiri JV Jenkins SA Parsons DL. Liposomes Drug Delivery System. Lanchaster Basel Switzerland: Technomic Publishing Co Inc; 1993:120"},{"key":"e_1_3_1_70_1","unstructured":"New RRC. Liposomes \u2013 a practical approach. Oxford University Press; 1990:137-40"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11746-007-1086-9"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.66.2573"},{"key":"e_1_3_1_73_1","unstructured":"New RRC. Liposomes \u2013 a practical approach. Oxford University Press; 1990:113"},{"key":"e_1_3_1_74_1","first-page":"163","volume":"72","author":"Carr","year":"1965","unstructured":"Carr RL. Evaluating flow properties of solids. Chem Eng 1965;72:163-168","journal-title":"Chem Eng"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(97)00058-1"},{"key":"e_1_3_1_76_1","first-page":"68","volume":"23","author":"Singh","year":"1999","unstructured":"Singh S. Drug stability testing and shelf life determination according to international guidelines. Pharm Tech 1999;23:68-86","journal-title":"Pharm Tech"},{"key":"e_1_3_1_77_1","unstructured":"ICH guidelines for stability testing of new drug substances and products. ICH Topic Q1A (R2); 2003:7"},{"key":"e_1_3_1_78_1","unstructured":"Aerosols Nasal Sprays Metered Dose Inhalers and Dry Powder Inhalers. USP 30 NF; 25 2007:601-7"},{"key":"e_1_3_1_79_1","unstructured":"Next Generation Pharmaceutical Impactor Applied Physics Inc Available from: http:\/\/www.appliedphysicsusa.com\/ngi_moudi.html [Last accessed on 9 October 2008]"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1208\/pt040454"},{"key":"e_1_3_1_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2006.07.012"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1972.222.2.409"},{"key":"e_1_3_1_83_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408449309104076"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-9351(76)90107-9"},{"key":"e_1_3_1_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6017(200008)89:8<1028::AID-JPS7>3.0.CO;2-3"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-003-0450-2"},{"key":"e_1_3_1_87_1","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2001.23.10.677118"},{"key":"e_1_3_1_88_1","unstructured":"Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration Rockville MD 2000. Available from: http:\/\/www.fda.gov\/cder\/guidance\/index.htm [Last assessed on 1 August 2008]"},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016212804288"},{"key":"e_1_3_1_90_1","first-page":"L134","volume":"258","author":"Dobbs","year":"1990","unstructured":"Dobbs LG. Isolation and culture of alveolar type II cells. Am J Physiol 1990;258:L134-47","journal-title":"Am J Physiol"},{"key":"e_1_3_1_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(89)90337-6"},{"key":"e_1_3_1_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6017(200002)89:2<223::AID-JPS9>3.0.CO;2-R"},{"key":"e_1_3_1_93_1","first-page":"L104","volume":"27","author":"Fang","year":"2004","unstructured":"Fang X, Song Y, Matthay MA, et al. Transport across cultured rat alveolar epithelial cells: a novel in vitro system. Am J Physiol 2004;27:L104-L110","journal-title":"Am J Physiol"},{"key":"e_1_3_1_94_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018887501927"},{"key":"e_1_3_1_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-002-0653-5"},{"key":"e_1_3_1_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2006.07.004"},{"key":"e_1_3_1_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10069"},{"key":"e_1_3_1_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2005.03.010"},{"key":"e_1_3_1_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/1061186031000086117"},{"key":"e_1_3_1_100_1","unstructured":"Patel G Misra A. Pulmonary Delivery of liposomal Dry Powder Inhaler of Formoterol for effective treatment of Asthma. Available from: http:\/\/www.aapspharmsci.org\/abstracts\/AM_2007\/AAPS2007-001080.PDF [Last accessed on 29 August 2008]"},{"key":"e_1_3_1_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00705-0"},{"key":"e_1_3_1_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2007.04.009"},{"key":"e_1_3_1_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.01.046"},{"key":"e_1_3_1_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1090"},{"key":"e_1_3_1_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh518"},{"key":"e_1_3_1_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2006.07.013"},{"key":"e_1_3_1_107_1","doi-asserted-by":"crossref","unstructured":"Changsan N Srichana T. Factors Influencing the Properties of Rifampicin Liposome and Applications for Dry Powder Inhaler. Nano\/Micro Engineered and Molecular Systems. 2nd IEEE International Conference. 16 \u2013 19 January; 2007:1104-9","DOI":"10.1109\/NEMS.2007.352211"},{"key":"e_1_3_1_108_1","author":"Changsan","year":"2008","unstructured":"Changsan N, Chan HK, Srichana T, et al. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 2008 May 15. DOI:10.1002\/jps.21441 [Epub ahead of print]","journal-title":"J Pharm Sci"},{"key":"e_1_3_1_109_1","doi-asserted-by":"publisher","DOI":"10.1080\/713840401"},{"key":"e_1_3_1_110_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018934810512"},{"key":"e_1_3_1_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.03.014"},{"key":"e_1_3_1_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(01)00143-6"},{"key":"e_1_3_1_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2003.09.019"},{"key":"e_1_3_1_114_1","unstructured":"Schreier HANS. Liposome Powders. WO1994028876; 1994"},{"key":"e_1_3_1_115_1","unstructured":"Misra A Padhi BK Chougule MB. Engineered Monodisperse Inhalation Powders for Effective Treatment of Lung Diseases IN228\/MUM\/2005; 2005"},{"key":"e_1_3_1_116_1","unstructured":"Misra A Padhi BK Chougule MB et al. Aerodynamically light porous dry powder inhaler formulations for targeted pulmonary deposition IN953\/MUM\/2006; 2006"},{"key":"e_1_3_1_117_1","unstructured":"Frank P. An Inhalation System. EP1128813; 2001"},{"key":"e_1_3_1_118_1","unstructured":"Roman PS Frank P. Methods for treating lung cancer. WO03015707A2; 2003"},{"key":"e_1_3_1_119_1","unstructured":"Bystrom K Nilsson P. Powders for inhalation. US6045828; 1996"},{"key":"e_1_3_1_120_1","unstructured":"Weers JG Tarara T Tzannis S. Lipid formulations for spontaneous drug encapsulation. US20050214224A1; 2005"},{"key":"e_1_3_1_121_1","unstructured":"Huang L Sorgi Frank L. A Dry Powder Formulation For Gene Delivery. WO1996027393; 1996"},{"key":"e_1_3_1_122_1","unstructured":"Taylor P William M Janet C. Liposomes Containing A Corticosteroids. WO1996022764; 1996"},{"key":"e_1_3_1_123_1","unstructured":"Wang Z Orszanska H Finlay W. Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery. US20060280691; 2006"},{"key":"e_1_3_1_124_1","unstructured":"Walter PR Vladimir M Paul MR. Formulations of DNAse and Methods of use thereof. WO2008039989; 2008"},{"key":"e_1_3_1_125_1","doi-asserted-by":"crossref","unstructured":"Clark A Shire SJ. Pulmonary delivery technology: recent advances and potential for the new millennium. Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker; NY; 2004:571-92","DOI":"10.1201\/9780203912898.ch19"},{"key":"e_1_3_1_126_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-200001000-00021"},{"key":"e_1_3_1_127_1","unstructured":"Multidose Safety and Tolerability Study of (Arikace\u2122) for Inhalation In Cystic Fibrosis Patients. Transave NCT00558844. November 2007. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00558844?intr=%22Amikacin%22&rank=9 [Last Accessed on 1 September 2008;]"},{"key":"e_1_3_1_128_1","unstructured":"Aradigm Reports Successful Top-Line Phase 2 Data With Inhaled Liposomal Ciprofloxacin For Cystic Fibrosis. Available from: http:\/\/www.medicalnewstoday.com\/articles\/113831.php [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_129_1","unstructured":"Aradigm Initiates Phase 2 Study of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Available from: http:\/\/www.reuters.com\/article\/pressRelease\/idUS103481+19-Jun-2008+BW2008061 9 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_130_1","unstructured":"Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis (AMBINEB). PETHEMA Foundation NCT00391014. April 2008. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00391014? term=NCT00391014&rank=1 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_131_1","unstructured":"Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients \u2013 Ambisome Study University of Pittsburgh Astellas Pharma US Inc NCT00177710 Dec 2007. Available from: http:\/\/clinicaltrials.gov\/ ct2\/show\/NCT00177710?term=liposomes+pulmonary&rank=3 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_132_1","unstructured":"Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis. Erasmus Medical Center Gilead Sciences Nexstar Pharmaceuticals NCT00263315 May 2006. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00263315?term=liposome+inhalation&rank=2 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_133_1","unstructured":"Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung. University of New Mexico NCT00277082. _ANY_. Available from: http:\/\/clinicaltrials.gov\/ ct2\/show\/NCT00277082?term= liposome+aerosol&rank=2 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_134_1","unstructured":"Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) University of New Mexico. NCT00250068. June 2007. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00250068?term=liposome+ aerosol&rank=3 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_135_1","unstructured":"Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC). University of New Mexico. NCT00249990 June 2007. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00249990? term=liposome+aerosol&rank=4 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_136_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200008000-00006"},{"key":"e_1_3_1_137_1","unstructured":"Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects (LEF-2495). YM BioSciences NCT00709254. Jan 2002. Available from: http:\/\/clinicaltrials.gov\/ ct2\/show\/NCT00709254?term=liposome+ inhalation&rank=3 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_138_1","unstructured":"Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects. YM BioSciences. NCT00708318. June 2002. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00708318?term=liposome+inhalation&rank=4 [Last accessed on 1 September 2008]"},{"key":"e_1_3_1_139_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb\/6.5.535"},{"key":"e_1_3_1_140_1","first-page":"709","author":"Li","year":"1995","unstructured":"Li X, et al. Short-term inflammatory responses following intratracheal instillations of fine and ultrafine carbon black in rats. Inhal Toxicol 1995;(11):709-31","journal-title":"Inhal Toxicol"},{"key":"e_1_3_1_141_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408449309104076"},{"key":"e_1_3_1_142_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S596"},{"key":"e_1_3_1_143_1","unstructured":"Henderson RF. Bronchoalveolar lavage: a tool for assessing the health status of the lung in Concepts in Inhalation Toxicology. In: McClellan R Hcnderson RF editors Hemisphere New York; 1988. p. 415"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17425240802652309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:46:46Z","timestamp":1770371206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17425240802652309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1517\/17425240802652309"],"URL":"https:\/\/doi.org\/10.1517\/17425240802652309","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}